Indocyanine Green for Detection of Sentinel Lymph Nodes In Comparison to ICG Plus Technetium in the Evaluation of Vulvar Squamous Cell Carcinoma

ConditionVulvar Cancer

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexFemale

Age18+

SponsorHamilton Health Sciences Corporation

About this trial

The aim of this study is to confirm prospectively if the use of near infrared-indocyanine green (NIR-ICG) alone offers similar accuracy and sensitivity to the gold standard dual technique for sentinel lymph node detection in early stage vulvar cancer.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

ICG alone

Treatment groups

58 Participants

are divided into 1 treatment group

Locations

Hamilton Health SciencesL8V5C2, HamiltonOntario, Canada

Sponsors and collaborators

Hamilton Health Sciences Corporation

Lead sponsor

Juravinski Cancer Centre Foundation

Collaborator

Source ClinicalTrials.gov